Trexor Adverse Reactions

Pemetrexed may cause fatigue, stomatitis, pharyngitis, dyspnea, chest pain, and neuropathy. Rare cases of hepatitis, colitis, and intestinal pneumonitis have occurred; fatalities have been reported. Serious renal events, including acute renal failure, have been reported. Serious renal events, including acute renal failure, have been reported with pemetrexed when it was used either alone or with other cytotoxic drugs; most patients had underlying risk factors such as dehydration, hypertension or diabetes. Cardiovascular events, including myocardial infarction and cerebrovascular events, have occurred rarely, usually when pemetrexed was used with other cytotoxic drugs. Cases of radiation pneumonitis and radiation recall have been reported in patients treated with radiotherapy. Hypersensitivity reactions may occur.
Pemetrexed produces bone marrow depression, usually mild to moderate, with leucopenia, anaemia and less frequently thrombocytopenia. The nadir of the white cell count usually occurs 7 to 14 days after a dose, with recovery by the thirds week. Gastrointestinal toxicity is also common with nausea and vomiting, diarrhea and anorexia: mucositis may occur. Reversible increases in liver enzyme values have occurred. Other adverse effects include weakness and malaise, fever, pain, headache, skin rashes, desquamation, arthralgia, muscle cramps, weight loss, dehydration, peripheral oedema, alopecia, increased sweating, taste disturbance, and conjunctivitis. The use of folinic acid 25 mg/m² every 6 hours intravenously has been suggested in licensed product information for patients who develop very severe toxicity.